USFDA conducts inspection at Biocon’s Bengaluru facility

United States Food and Drug Administration (USFDA) has conducted a pre-approval inspection of Biocon’s new Oral Solid Dosage Forms manufacturing facility at Bengaluru from November 05 to 09. The audit concluded without any observations and no Form 483 was issued.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient’s worldwide.

BREAKING NEWS:
Samsung Galaxy S25 series price cut by ₹30,000 in India! Airtel’s 30-Day Plans: Up to 60GB Data, Unlimited Calls! Samsung Galaxy S25 series gets ₹30,000 price cut in India!